PRIVA-CANDESARTAN TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
16-06-2016
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CANDESARTAN CILEXETIL
Beschikbaar vanaf:
PHARMAPAR INC
ATC-code:
C09CA06
INN (Algemene Internationale Benaming):
CANDESARTAN
Dosering:
32MG
farmaceutische vorm:
TABLET
Samenstelling:
CANDESARTAN CILEXETIL 32MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
Prescription
Therapeutisch gebied:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Product samenvatting:
Active ingredient group (AIG) number: 0135220004; AHFS:
Autorisatie-status:
CANCELLED PRE MARKET
Autorisatie datum:
2018-03-06
Productkenmerken
_Priva-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35 _
_ _
PRODUCT MONOGRAPH
PR
PRIVA-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
PHARMAPAR INC.
DATE OF PREPARATION:
5950, Côte de Liesse, Suite 100
June 15, 2016
Ville Mont-Royal
Québec H4T 1E2
SUBMISSION CONTROL #: 194899
_Priva-CANDESARTAN _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35 _
_ _
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................................
4
ADVERSE REACTIONS
...........................................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................................
16
OVERDOSAGE
.......................................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
19
STORAGE AND STABILITY
.................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................
Lees het volledige document
